CRC Research Update — May 25, 2026
Today's colorectal cancer research highlights
Archive
A collection of 715 issues
Latest
Quality of life data for watch-and-wait versus surgery
Skip to content
The CRC Digest
Quality of life data for watch-and-wait versus surgery
Study provides quality of life comparisons to help rectal cancer patients and clinicians weigh treatment options after complete response. (Clinical Colorectal Cancer)
This content is informational only and does not constitute medical advice.
Always consult your
Cost analysis of risk-stratified screening based on FIT results
Skip to content
The CRC Digest
Cost analysis of risk-stratified screening based on FIT results
Real-world data examined resource use and costs of a low-risk screening approach for people with previous negative fecal immunochemical tests. (Clinical Colorectal Cancer)
This content is informational only and does not constitute medical advice.
Always
Practical guidance for integrating ctDNA testing into clinical care
Skip to content
The CRC Digest
Practical guidance for integrating ctDNA testing into clinical care
A narrative review summarizes evidence for ctDNA minimal residual disease testing in gastrointestinal cancers, with strongest data supporting use in resected stage II colon cancer. (Clinical and Translational Oncology)
This content is informational only and
KRAS G12D-targeted therapy tested in preclinical models
Skip to content
The CRC Digest
KRAS G12D-targeted therapy tested in preclinical models
A nanomedicine delivering a KRAS G12D inhibitor showed promise in laboratory models of metastatic colorectal cancer. (Journal of Controlled Release)
This content is informational only and does not constitute medical advice.
Always consult your oncologist or care
RAS/BRAF wild-type patients: Maintenance strategies compared
Skip to content
The CRC Digest
RAS/BRAF wild-type patients: Maintenance strategies compared
Three trials pooled data on left-sided, RAS/BRAF wild-type metastatic CRC to compare toxicity profiles of different maintenance approaches. (Journal of the National Cancer Institute)
This content is informational only and does not constitute medical advice.
Always
CRC Research Finding
Skip to content
The CRC Digest
◇ Experimental nanomedicine targets KRAS G12D mutation in metastatic colorectal cancer
Preclinical research describes a macrophage-hitchhiking delivery system combining gemcitabine and a KRAS G12D inhibitor that improved drug delivery to lung metastases and triggered immune responses in colorectal cancer models. (Journal of Controlled Release)
This
CRC Research Update — May 24, 2026
Today's colorectal cancer research highlights
CRC Research Finding
Skip to content
The CRC Digest
◆ Updated survival analysis for bevacizumab in metastatic CRC
(Clinical Colorectal Cancer)
This content is informational only and does not constitute medical advice.
Always consult your oncologist or care team.
© 2026 The CRC Digest —
crcdigest.com
CRC Research Update — May 23, 2026
Today's colorectal cancer research highlights